Comparison
CJC-1295 with DAC vs without DAC: A Research Comparison
A research-focused comparison of CJC-1295 with DAC and without DAC — the Drug Affinity Complex, circulating duration and analytical distinction.
Quick Answer
CJC-1295 with DAC and without DAC are two forms of the same GHRH analogue, differing only in the presence of an albumin-binding Drug Affinity Complex. The DAC form has an extended circulating duration, while the without-DAC form is shorter-acting. Both engage the GHRH receptor, and the two are distinguished analytically by their different molecular masses.
CJC-1295 with DAC and CJC-1295 without DAC are two forms of the same growth hormone–releasing hormone (GHRH) analogue, differing only in the presence of a Drug Affinity Complex. The "DAC" group is a chemical modification that binds reversibly to albumin and extends the peptide’s circulating duration, making the choice between the two a matter of pharmacokinetics rather than of basic mechanism.
This page is a non-promotional scientific reference for researchers. It does not provide performance, anti-ageing, therapeutic, or human-use guidance. Both forms supplied by Bulk Aussie Peptides are for laboratory research purposes only.
At a Glance
Both forms engage the GHRH receptor and promote growth hormone release through the same pathway. The difference is duration: the DAC form circulates longer because of albumin binding, while the without-DAC form has a shorter circulating duration.
Compare the Two Forms
- Receptor target: the GHRH receptor in both cases.
- Modification: CJC-1295 with DAC carries an albumin-binding Drug Affinity Complex; CJC-1295 without DAC does not.
- Circulating duration: extended in the DAC form; shorter in the without-DAC form.
- Molecular mass: the DAC-modified form is heavier, reflecting the added group, which is visible in mass spectrometry.
- Research use: the DAC form is used to study sustained GHRH-receptor activation; the without-DAC form is used where a shorter duration is preferred or to isolate the effect of the DAC group itself.
Why the Difference Matters in Research
The duration of receptor exposure is a key variable in growth-hormone research design. Comparing the two forms allows researchers to separate the effects of extended receptor exposure from those of the underlying GHRH-analogue structure. Findings remain preclinical.
Analytical Testing
Both forms are characterised using HPLC for purity and mass spectrometry for identity. The difference in molecular mass between the two forms is a reliable distinguishing signal. See how to read a peptide Certificate of Analysis.
Individual References
About this page. This article is a non-promotional reference prepared by the Bulk Aussie Peptides research team for educational purposes. It is not medical advice and does not provide dosage, injection, therapeutic, or human-use guidance. Product information is for laboratory research only. How we write and review our research library · Report a correction
Related Articles
Individual Compound Research
CJC-1295 with DAC: A Laboratory Research Reference
A non-promotional scientific reference on CJC-1295 with DAC — GHRH analogue identity, the Drug Affinity Complex modification, molecular characteristics and analytical testing.
Individual Compound Research
CJC-1295 without DAC: A Laboratory Research Reference
A non-promotional scientific reference on CJC-1295 without DAC — unmodified GHRH analogue identity, molecular characteristics, mechanism as studied and analytical testing.
Explore the Research Library
Browse our collection of educational reference material.
View All Articles